1+ hour, 12+ min ago   (437+ words) Federal grants have helped keep Medicare Part D prescription drug costs down, but they’re set to end next year. They say being a smart shopper is the first step to financial stability. “It’s always important to revisit Medicare decisions, but…...

9+ hour, 54+ min ago   (513+ words) Bill Bengen never intended for the recommendation to become a baseline for retirement income spending, despite its popularity among prominent financial planners. If you’re reading Retirement Upside, you’ve probably heard of the 4% rule. “I never intended it to be a…...

1+ week, 1+ day ago   (428+ words) The projection is up 7.5% from last year, and marks the largest annual jump in more than a decade, according to a new Fidelity study. Sorry to alarm you, but one of the biggest expenses your clients will face in retirement…...

4+ week, 1+ hour ago   (431+ words) They can result in many thousands of dollars in excess costs and even jeopardize access to care in the worst cases. Not everything your clients hear on the pickleball court is true. “You’ve got the opportunity to save clients a…...

4+ mon, 1+ week ago   (405+ words) Scary stats about the cost of health care in retirement drive many to simply ignore the issue, resulting in missed planning opportunities. It’s natural to look away from things that worry us, but ignoring problems just makes them worse. Nearly…...

4+ mon, 2+ week ago   (245+ words) Getting the most out of Medicare requires regular reevaluation and carefully balancing risks with costs, experts say. More than 11,000 Americans will turn 65 every day this year, reaching the age when they can claim Medicare benefits. “When I first started writing…...

4+ mon, 3+ week ago   (352+ words) After years of aggressive expansion, many Medicare Advantage plans are recalibrating popular extras and changing costs. What goes up must come down. “The current environment is forcing plans to rebalance benefits,” Hopkin Bishop told Retirement Upside. “Are higher out-of-pocket costs…...

8+ mon, 4+ week ago   (356+ words) AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange. Pharmaceutical companies around the world are under massive pressure from President Donald Trump to lower drug prices and manufacture them on American…...